215 related articles for article (PubMed ID: 22301393)
1. Eosinophilia during psoriasis treatment with TNF antagonists.
Malisiewicz B; Murer C; Pachlopnik Schmid J; French LE; Schmid-Grendelmeier P; Navarini AA
Dermatology; 2011; 223(4):311-5. PubMed ID: 22301393
[No Abstract] [Full Text] [Related]
2. Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists.
Carlesimo M; La Pietra M; Arcese A; Di Russo PP; Mari E; Gamba A; Orsini D; Camplone G
Int J Dermatol; 2012 Oct; 51(10):1234-6. PubMed ID: 22416995
[No Abstract] [Full Text] [Related]
3. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
Woolf RT; Smith CH; Robertson K; Barker JN
Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
[No Abstract] [Full Text] [Related]
4. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
Leman J; Burden AD
Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
[TBL] [Abstract][Full Text] [Related]
5. The evolving role of biologics in the treatment of pediatric psoriasis.
Luu M; Cordoro KM
Skin Therapy Lett; 2013 Feb; 18(2):1-4. PubMed ID: 23508772
[TBL] [Abstract][Full Text] [Related]
6. Anti-TNF-alpha therapy in childhood pustular psoriasis.
Pereira TM; Vieira AP; Fernandes JC; Antunes H; Basto AS
Dermatology; 2006; 213(4):350-2. PubMed ID: 17135745
[No Abstract] [Full Text] [Related]
7. Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors.
Meyer MW; Zachariae C; Bendtzen K; Skov L
Acta Derm Venereol; 2012 Jul; 92(4):362-4. PubMed ID: 22864558
[No Abstract] [Full Text] [Related]
8. Adalimumab vs. etanercept in psoriasis.
Downs AM
Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
[No Abstract] [Full Text] [Related]
9. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
Wu JJ; Poon KY; Bebchuk JD
J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
[TBL] [Abstract][Full Text] [Related]
10. [Intermittent treatment regimens and the rational (efficient) use of biologic agents in psoriasis].
Moreno-Ramírez D
Actas Dermosifiliogr; 2011 May; 102(4):241-3. PubMed ID: 21481332
[No Abstract] [Full Text] [Related]
11. [Psoriasis updates].
Boulinguez S
Ann Dermatol Venereol; 2010 May; 137(5 Suppl 1):1-4. PubMed ID: 20510173
[No Abstract] [Full Text] [Related]
12. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
Rallis E; Verros CD
Dermatol Online J; 2011 Apr; 17(4):14. PubMed ID: 21549089
[No Abstract] [Full Text] [Related]
13. A scientific debate: key clinical questions in the management of psoriasis.
Stingl G
J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():1. PubMed ID: 22758910
[No Abstract] [Full Text] [Related]
14. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study.
Gallo E; Cabaleiro T; Román M; Solano-López G; Abad-Santos F; García-Díez A; Daudén E
Br J Dermatol; 2013 Oct; 169(4):819-29. PubMed ID: 23662788
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis.
Gualdi G; Monari P; Rossi MT; Crotti S; Calzavara-Pinton PG
Br J Dermatol; 2012 Jun; 166(6):1373-4. PubMed ID: 22212112
[No Abstract] [Full Text] [Related]
16. Long-term management of erythrodermic psoriasis with anti-TNF agents.
Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing seasonal patterns of relapse in anti-TNF psoriatic responders after temporary drug discontinuation.
Ruano J; Velez A; Casas E; Rodriguez-Martin A; Salido R; Isla-Tejera B; Espejo-Alvarez J; Gómez F; Jiménez-Puya R; Moreno-Giménez JC
J Eur Acad Dermatol Venereol; 2014 Apr; 28(4):516-8. PubMed ID: 23841941
[No Abstract] [Full Text] [Related]
18. Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders.
Hession MT; Gottlieb AB
J Dermatolog Treat; 2011 Apr; 22(2):90-101. PubMed ID: 20673155
[TBL] [Abstract][Full Text] [Related]
19. The return of investment of translational research in inflammatory dermatoses.
van de Kerkhof PC
J Dermatolog Treat; 2008; 19(6):317. PubMed ID: 18982511
[No Abstract] [Full Text] [Related]
20. Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial.
Prinz JC; Fitzgerald O; Boggs RI; Foehl J; Robertson D; Pedersen R; Molta CT; Freundlich B
J Eur Acad Dermatol Venereol; 2011 May; 25(5):559-64. PubMed ID: 20840349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]